Ipilimumab

MCE 国际站：Ipilimumab

产品活性：Ipilimumab 是一种全人类单克隆抗体 IgG1κ，可阻断 T 细胞上的抑制性受体细胞毒性 T 淋巴细胞抗原4（CTLA-4）。Ipilimumab 可用于不可切除或转移性黑色素瘤（MM）研究。

作用靶点：CTLA-4

In Vitro: Ipilimumab inhibits CTLA-4, allowing the T cell immune response to be reactivated against tumor cells. Ipilimumab can promote antitumor activity as a single agent or in combination with cytokines, chemotherapy, or vaccines.
Ipilimumab (0, 5 or 50 μg/ mL, 6 days) alone can enhance IL-2 production and in combination with nivolumab stimulate higher IL-2 release in peripheral blood mononuclear cells (PBMC). And the combination of ipilimumab and nivolumab treatment synergistically enhances effector and memory T-cell responses.

In Vivo: Ipilimumab (i.v., 3 or 10 mg/kg, once a week for 4 weeks) combination with nivolumab (10 or 50 mg/kg) results in gastrointestinal inflammation in crab-eating monkeys and is associated with reduced albumin, increases globulin and increases neutrophil and eosinophil counts and mononuclear inflammation of the large intestine. Recurrent diarrhoea is demonstrated in the high-dose group, which also has visible degranulation of glandular blast cells in the pancreas.

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。